Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PMGC Holdings ( (ELAB) ) just unveiled an announcement.
On March 24, 2026, Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., executed a third amendment to its license agreement with Korea’s MOA Life Plus Co., Ltd., originally signed on April 30, 2024. The amendment replaces the prior milestone schedule, revising Exhibit C to update required achievements across the licensed field, including specific phases of pre-clinical trials and associated events tied to Investigational New Drug applications, along with adjusted timelines.
Under the new terms, PMGC is required to make a monetary payment to MOA within 30 days of the effective date as consideration for the revised milestone framework. The changes refine the development roadmap and timing obligations between the partners, potentially impacting how Northstrive and MOA coordinate their R&D activities and manage progress toward key regulatory submissions.
The most recent analyst rating on (ELAB) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on PMGC Holdings stock, see the ELAB Stock Forecast page.
Spark’s Take on ELAB Stock
According to Spark, TipRanks’ AI Analyst, ELAB is a Neutral.
The score is held down primarily by weak financial fundamentals (ongoing losses and significant cash burn) and strongly bearish technical momentum (price well below major moving averages with oversold indicators). A positive pipeline-related corporate update provides some support, but valuation is not meaningfully assessable from the provided P/E and dividend data.
To see Spark’s full report on ELAB stock, click here.
More about PMGC Holdings
PMGC Holdings Inc., through its wholly owned subsidiary Northstrive Biosciences Inc., operates in the biosciences and pharmaceutical development sector, focusing on pre-clinical research and the advancement of drug candidates toward Investigational New Drug applications. The company collaborates with international partners such as Korea-based MOA Life Plus Co., Ltd. to develop its pipeline within defined therapeutic fields and milestones.
Average Trading Volume: 562,394
Technical Sentiment Signal: Sell
Current Market Cap: $1.01M
For an in-depth examination of ELAB stock, go to TipRanks’ Overview page.